Work

OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) monotherapy vs standard-of-care for ER+, HER2- advanced or metastatic breast cancer patients after endocrine therapy and CDK4/6 inhibitors.

Year: 2025

Type: article

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.tps1131

Authors: Barbara Pistilli, Joohyuk Sohn, Peter Schmid, Meritxell Bellet, Lucia Del Mastro, Jane Lowe Meisel, Arlene Chan, Elisabeth de Kermadec, Lianqing Zheng, Heather L. McArthur

Institutions: Institut Gustave Roussy, Fondation Gustave Roussy, Yonsei University, Barts Cancer Institute, Vall d'Hebron Institute of Oncology, Ospedale Policlinico San Martino, Emory University, Winship Cancer Institute, Curtin University, Olema Pharmaceuticals (United States), The University of Texas Southwestern Medical Center

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410804850

FWCI: 1.772

Cites:

Cited by: 3

Related to: 10